玻璃体内注射替奈普酶作为富血小板血浆和骨髓间充质细胞治疗增生性糖尿病视网膜病变和黄斑水肿的辅助治疗：一项荟萃分析。

METHODOLOGY/PRINCIPAL FINDINGS: We conducted a meta-analysis and searched for reports concerning IVTA injection combined with PRP for the treatment of PDR and DME using Medline, EMbase, Web of Science, the Cochrane Library, and Google according to Cochrane evaluation guidelines. The quality of the reports was evaluated using the Jadad score. Only four studies were ultimately included in this meta-analysis and the fixed-effects model was used. Treatment with IVTA injection combined with PRP and MPC significantly improved BCVA (p<0.001) from one to six months, compared with PRP and MPC alone. There was a statistically significant mean difference in central macular thickness (CMT), at the one-month follow-up (p<0.001). No evidence of publication bias was present. There was a low level of heterogeneity in this group of studies.

CONCLUSIONS/SIGNIFICANCE: This meta-analysis indicates that IVTA injection combined with PRP and MPC results in an improvement of BCVA, and CMT reduction in patients with PDR and DME.

背景

定量评估玻璃体内曲安奈德（IVTA）注射、全视网膜光凝（PRP）和黄斑光凝（MPC）联合治疗增生型糖尿病视网膜病变（PDR）和糖尿病性黄斑水肿（DME）患者的疗效。

方法/主要发现：我们按照 Cochrane 评价指南，通过 Medline、EMbase、Web of Science、Cochrane 图书馆和 Google 检索有关 IVTA 注射联合 PRP 治疗 PDR 和 DME 的报告，进行荟萃分析。使用 Jadad 评分评估报告质量。最终有四项研究纳入本荟萃分析，采用固定效应模型。与 PRP 和 MPC 单独治疗相比，IVTA 注射联合 PRP 和 MPC 治疗可显著改善治疗后 1 至 6 个月时的 BCVA（p<0.001）。在 1 个月随访时，中心黄斑厚度（CMT）有统计学显著差异（p<0.001）。未见发表偏倚证据。这组研究的异质性水平较低。

结论/意义：本荟萃分析表明，IVTA 注射联合 PRP 和 MPC 可改善 PDR 和 DME 患者的 BCVA，并降低 CMT。